Feed GLSI
GL
Greenwich LifeSciences, Inc. GLSI NASDAQ · Healthcare · United States
$15.28 -5.03% -$0.81
Summary
22 / 100 · Bulios Score
Valuation 0Growth 0Profitability -Quality 0Debt 92Stability 37
What speaks for it
- It has no debt and holds $8.88M in cash.
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveIs it growing?
It is shrinkingRevenue (USD)
202120222023202420252027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $21.7M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $8.88M
Debt $0.00
Free cash flow over 12 months -$12.5M
It has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 0
- Sell 0
Today's price within the analysts' price targets
Today's price $15.28 Average target $50
$15.28 $50
The average target of $50 is 227% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.